GSK Sees Light At End Of Shingrix Tunnel As COVID-19 Eases

Company Records Steep Sales Decline For Shingles Vaccine in Q1

A CDC recommendation slowed non-pandemic vaccinations, but Shingrix shots will likely increase as more eligible consumers are fully vaccinated against SARS-CoV-2.

Shingles_1200
GSK forecasts stronger sales for its shingles vaccine, Shingrix, in the latter half of 2021 and 2022 • Source: Shutterstock

More from Earnings

More from Business